Docket #: S21-211
Thiourea-enhanced antimicrobial peptoids as a treatment against antibiotic resistant microbes
Antimicrobial peptoids are promising leads for novel antibiotics; however, their activity is often compromised under physiological conditions. Inventors at Stanford enhanced the efficacy of antimicrobial peptoids by using thiourea and thiourea derivatives. The minimum inhibitory concentration (MIC) of antimicrobial peptoids against Pseudomonas aeruginosa, Staphylococcus aureus, and Ciprofloxacin-resistant Klebsiella pneumoniae significantly decreased when determined in the presence of thiourea as compared to antimicrobial peptoid only. In addition, combination with thiourea enhances the efficacy of antimicrobial peptoids against bacterial biofilms. The combination of thiourea with antimicrobial peptoids has potential to be used in therapeutic applications to treat acute and chronic bacterial infections.
Applications
- Antibiotic medications
- Antibacterial products
Advantages
- Enhances efficacy of treatment against antibiotic-resistant bacteria
- Can be used with gram-positive and gram-negative bacteria
- Does not synergize with the peptoid, preventing unwanted mutations to the compound
Patents
- Published Application: WO2023288065
Similar Technologies
-
Anti-AF5 monoclonal antibody S08-139Anti-AF5 monoclonal antibody
-
Lectin-Drug Conjugates Enable Selective Cytotoxicity to Treat Cancer or other Diseases S23-430Lectin-Drug Conjugates Enable Selective Cytotoxicity to Treat Cancer or other Diseases
-
Monoclonal antibody to CD6, Clone 34-3 S16-098Monoclonal antibody to CD6, Clone 34-3